Dr. John Bell
Dr. John Bell and his team have been investigating cancer-fighting (oncolytic) viruses at Ottawa Hospital Research Institute for more than 10 years.Through his work with BioCanRx, Dr Bell and his team are focused on translating promising cancer immune therapy approaches using novel viral vaccines against specific tumour antigens, and by the use of engineered immune cells modified to recognize a patient's own tumour.
In addition, researchers from the Ottawa Hospital Research Institute (OHRI), the University of Ottawa (uOttawa), Jennerex Inc. and several other institutions reported promising results of a world-first cancer therapy trial in renowned journal Nature.
The trial is the first to show that an intravenously-delivered viral therapy can consistently infect and spread within tumours without harming normal tissues in humans.
Cancer: Intravenously-delivered viral therapy
- Date modified: